(Q46018304)

English

The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice.

scientific article published on 2 February 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428830

The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428830

1 reference

based on heuristic

inferred from title

author name string

J Kovacs-Nolan

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428830

L Latimer

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428830

A Landi

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428830

H Jenssen

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428830

R E W Hancock

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428830

L A Babiuk

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428830

S van Drunen Littel-van den Hurk

7

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428830

language of work or name

0 references

publication date

2 February 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428830

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428830

27

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428830

14

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428830

2055-2064

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428830

IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Rationally-designed vaccine adjuvants: separating efficacy from toxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Recent developments in adjuvants for vaccines against infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Immunological concepts of vaccine adjuvant activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

CpG motifs as immune adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Mechanisms of stimulation of the immune response by aluminum adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

The science of adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Immunotherapeutic uses of CpG oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

CpG DNA induces stronger immune responses with less toxicity than other adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Cationic host defense (antimicrobial) peptides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Cationic peptides: effectors in innate immunity and novel antimicrobials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Alarmins: chemotactic activators of immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

The cathelicidins--structure, function and evolution

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Immunomodulatory activities of small host defense peptides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Structural and DNA-binding studies on the bovine antimicrobial peptide, indolicidin: evidence for multiple conformations involved in binding to membranes and DNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Polyphosphates and other phosphorus-containing polymers for drug delivery applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Protein release from polyphosphazene matrices

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Synthesis and biologically relevant properties of polyphosphazene polyacids

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Immunogenicity of bovine herpesvirus 1 glycoprotein D in mice: effect of antigen form on the induction of cellular and humoral immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

The in vivo effects of recombinant bovine herpesvirus-1 expressing bovine interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Sterically Stabilized Cationic Liposomes Improve the Uptake and Immunostimulatory Activity of CpG Oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a TH2-type immune response to co-injected antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Vaccine protocols for enhanced immunogenicity of exogenous antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Incorporation of CpG oligonucleotide ligand into protein-loaded particle vaccines promotes antigen-specific CD8 T-cell immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Dendritic cell regulation of TH1-TH2 development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Cathelicidins: microbicidal activity, mechanisms of action, and roles in innate immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Polyarginine enters cells more efficiently than other polycationic homopolymers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.118

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.01.118

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428830

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428830

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46018304&oldid=1368959645"